JADENU Drug Patent Profile

Which patents cover Jadenu, and what generic alternatives are available?

Jadenu is a drug marketed by Novartis Pharms Corp and Novartis and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in forty-three countries.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the deferasirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jadenu

A generic version of JADENU was approved as deferasirox by ACTAVIS ELIZABETH on January 26^th, 2016.

Summary for JADENU

International Patents:	68
US Patents:	1
Applicants:	2
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for JADENU

Paragraph IV (Patent) Challenges for JADENU

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
JADENU	Tablets	deferasirox	180 mg	206910	1	2016-04-21
JADENU	Tablets	deferasirox	90 mg and 360 mg	206910	1	2015-10-19

US Patents and Regulatory Information for JADENU

JADENU is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-001	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-001	May 18, 2017	AB	RX	Yes	No
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-002	Mar 30, 2015	AB	RX	Yes	No	9,283,209		Y	Y
Novartis Pharms Corp	JADENU	deferasirox	TABLET;ORAL	206910-003	Mar 30, 2015	AB	RX	Yes	Yes	9,283,209		Y	Y
Novartis	JADENU SPRINKLE	deferasirox	GRANULE;ORAL	207968-003	May 18, 2017	AB	RX	Yes	Yes

International Patents for JADENU

See the table below for patents covering JADENU around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2018162255
World Intellectual Property Organization (WIPO)	9749395
Malaysia	170303
Georgia, Republic of	P20186810
Germany	122007000020

Supplementary Protection Certificates for JADENU

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0914118	06C0049	France		PRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
0914118	SPC/GB07/002	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0914118	CA 2006 00035	Denmark
0914118	SPC 035/2006	Ireland		SPC 035/2006: 20070528, EXPIRES: 20210827
0914118	300248	Netherlands		300248, 20170624, EXPIRES: 20210827

Investment Scenario and Fundamentals Analysis for JADENU (Deferasirox)

Last updated: February 20, 2026

What is the current market and patent status of JADENU?

JADENU (deferasirox) is an oral iron chelator developed by Novartis, approved for treating chronic iron overload caused by blood transfusions in conditions such as thalassemia, sickle cell anemia, and certain other anemias. It entered the market in 2013 and faces patent life until approximately 2028.

The drug's market exclusivity is maintained primarily through patented formulations and dosing regimens. Its patent protection includes a primary patent expiring in 2028, with additional patents filed to extend the market exclusivity, potentially up to 2030. Patent challenges or generic entries could influence revenues post-expiration.

How does JADENU's market penetration compare to competitors?

JADENU's primary competitors are Ferriprox (deferiprone, sold by Apotex) and Exjade (generic form of deferasirox, also by Novartis pre-JADENU). JADENU's advantages include twice-daily dosing and improved tolerability compared to Exjade.

In terms of sales, JADENU generated approximately $1.35 billion globally in 2022, representing about 70% of the deferasirox market, according to IQVIA data. The rest of the market comprises generic formulations and products like Ferriprox, which serve niche segments.

Market share has remained stable due to the device's branded status, but upcoming patent expirations threaten retention of pricing power and sales volume.

What are the clinical and development pipeline fundamentals for JADENU?

JADENU has established efficacy and safety for chronic iron overload indications. Novartis is investing into new formulations and dosing strategies to extend its use.

Pivotal trials for pediatric populations (ages 2-16) demonstrated comparable safety and efficacy to adult treatment. Additionally, trials combining deferasirox with other agents are ongoing, aiming to expand indications.

No significant late-stage pipeline drugs are publicly announced as replacements or successors, but developments include a longer-acting formulation and a potential biosimilar entry planned around 2025. These developments could influence future revenues.

What regulatory and reimbursement factors impact investment?

JADENU has received approvals from FDA, EMA, and other major regulators. Reimbursement remains stable in developed markets, supported by standard-of-care status in transfusional iron overload. Pricing policies have kept net prices high, but these are under scrutiny in cost-containment efforts.

Post-2028, generic entries are expected, which could reduce prices by 50-70% depending on regional policies. Patent litigation, such as Novartis’ ongoing patent defenses, could extend exclusivity.

What is the financial outlook and risk profile?

JADENU’s peak sales occurred in 2021, driven by increasing prevalence of transfusional iron overload. Despite the patent expiration risks, Novartis maintains a robust pipeline projecting maintenance of market share through incremental innovations.

Risks include:

• Patent expiration leading to revenue erosion.
• Regulatory delays affecting pipeline approval.
• Competition from generics and other chelators.
• Pricing pressures across healthcare systems.

Projected revenues are expected to decline 20-30% over the next five years if patent expiry accelerates and generic penetration increases.

What are the key competitive advantages and challenges?

Advantages:

• Established clinical efficacy.
• Market leader position.
• Strong regulatory backing.
• Well-characterized safety profile.

Challenges:

• Patent lifecycle expiration risks.
• Competition from lower-cost generics.
• Limited pipeline additions specifically targeting iron overload.
• Pricing pressures in public healthcare markets.

Summary

JADENU's market is mature, with sustained revenues driven by its clinical benefits and market positioning. The expiration of key patents around 2028 poses a significant risk to its revenue streams. Novartis's ongoing investments into formulations and incremental improvements may slow revenue erosion, but newer competitive pressures and patent challenges could accelerate decline.

Key Takeaways

• JADENU has maintained a strong market position through patent protection and clinical advantages.
• Patent expiration by 2028 poses a primary revenue risk; generic entries are likely thereafter.
• The drug's future growth depends on pipeline advancement and regulatory extensions.
• Market competition from cheaper generics and alternative chelators influences pricing and sales volumes.
• Strategic positioning, such as formulation innovation and geographic expansion, may mitigate revenue decline post-2028.

FAQs

1. When do key patents for JADENU expire?
Most primary patents are set to expire in 2028, with additional patents potentially extending exclusivity to 2030.

2. What are the major competitors of JADENU?
Main competitors are Ferriprox (deferiprone) and generic deferasirox formulations like Exjade.

3. How vulnerable is JADENU to generic competition?
Post-2028, generic deferasirox will likely dominate the market, causing significant price reductions.

4. What growth opportunities exist beyond 2028?
Potential growth depends on new formulations, expanded indications, and geographic market expansion.

5. How does reimbursement affect JADENU’s market outlook?
Stable in developed markets, but increasing pricing pressure and healthcare cost containment could impact profitability.

---

References

[1] IQVIA. (2022). Global Oncology and Hematology Market Data.
[2] Novartis. (2022). JADENU regulatory filings and approval summaries.
[3] European Medicines Agency. (2021). Summary of Product Characteristics for JADENU.
[4] U.S. Food and Drug Administration. (2013). Approval Letter for JADENU.
[5] MarketWatch. (2022). Hematology drug market trends and competitive analysis.